Managed Access Programs for SEG101, Crizanlizumab
Clinical trial NCT03720626 · AVAILABLE
Trial details
- NCT number
- NCT03720626
- Sponsor
- Novartis Pharmaceuticals
- Status
- AVAILABLE
- Study type
- EXPANDED_ACCESS
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.